Cevimeline is a cholinergic agonist that primarily promotes salivation by stimulating M receptors in the salivary glands.

I. Indications

1. Core Indication

Cevimeline is indicated only for the improvement of oral dryness symptoms in patients with Sjögren's syndrome.

2. Prerequisites for Use

(1) A definite diagnosis of Sjögren's syndrome must be established before use.

(2) If the therapeutic effect is not obvious after administration, long-term blind continuation of the drug should be avoided.

II. Contraindications

Cevimeline is strictly prohibited in the following patients.

1. Severe Ischemic Heart Disease

(1) Contraindicated in patients with myocardial infarction, angina pectoris, etc.

(2) This drug may exacerbate coronary artery spasm, worsening ischemic heart disease.

2. Bronchial Asthma and COPD

This drug may cause bronchoconstriction and increased mucus secretion, aggravating dyspnea.

3. Gastrointestinal or Bladder Neck Obstruction

This drug may contract or tense the muscles of the digestive tract and bladder, worsening obstructive symptoms.

4. Epilepsy

May provoke epileptic seizures.

5. Parkinson's Disease or Parkinsonism

May worsen motor symptoms.

6. Iritis

Miotic effect may aggravate ocular inflammation.

III. Contraindicated Foods and Drug Interactions

1. Drugs to Avoid or Use with Caution

(1) Other cholinergic drugs (e.g., acetylcholine, bethanechol): Concomitant use enhances muscarinic effects, increasing the risk of adverse reactions.

(2) Cholinesterase inhibitors (e.g., neostigmine): Also enhance the effects of this drug.

(3) Anticholinergic drugs (e.g., atropine, scopolamine, phenothiazine antipsychotics, tricyclic antidepressants): May antagonize the efficacy of this drug.

(4) CYP2D6 or CYP3A4 inhibitors (e.g., quinidine, itraconazole, erythromycin, cimetidine): May increase the plasma concentration of this drug, raising the risk of adverse effects.

(5) CYP450 inducers: May reduce the efficacy of this drug.

2. Contraindicated Foods

To reduce gastrointestinal adverse effects (incidence of nausea, abdominal pain, etc., approximately 10%), it is recommended:

(1) Take strictly after meals, avoid taking on an empty stomach.

(2) Avoid greasy, spicy, excessively cold or hot foods during treatment to prevent gastrointestinal irritation.

(3) Avoid excessive alcohol consumption, as alcohol may increase the burden on liver metabolism.

IV. Use in Special Populations

1. Patients with Comorbidities (Use with Caution)

The following patients may experience worsening of their underlying disease when using this drug. It should be used cautiously under physician assessment and monitoring:

(1) Severe salivary gland pain/swelling: May aggravate symptoms.

(2) Interstitial pneumonia: May worsen the condition. If dyspnea occurs, discontinue the drug and administer corticosteroid therapy.

(3) Pancreatitis: Increased pancreatic secretion may worsen the condition.

(4) Irritable bowel syndrome: Increased intestinal motility may worsen diarrhea.

(5) Peptic ulcer: Increased digestive fluid secretion may aggravate the ulcer.

(6) Gallbladder disease or gallstones: Bile duct contraction may worsen symptoms.

(7) Urinary tract stones or kidney stones: Ureteral contraction may aggravate obstruction.

(8) Prostatic hyperplasia with voiding difficulty: Bladder muscle tension may worsen dysuria.

(9) Hyperthyroidism: May induce arrhythmia or atrial fibrillation.

(10) Systemic sclerosis: May affect the cardiovascular and digestive systems.

2. Patients with Renal Impairment

Plasma concentrations may remain persistently elevated, increasing the incidence of adverse effects. Caution is required.

3. Patients with Hepatic Impairment

Similarly, there is a risk of elevated plasma concentrations. Use under physician guidance.

4. Pregnant Women

Use only if the therapeutic benefit outweighs the risk.

5. Breastfeeding Women

(1) Animal studies show that the drug can be excreted into milk.

(2) The decision to continue or discontinue breastfeeding should be made after weighing the therapeutic benefit against the benefit of breastfeeding.

6. Children

No clinical trial data are available in children; use is not recommended.

7. Elderly

Elderly patients often have decreased hepatic and renal function, making them prone to persistently elevated plasma concentrations. Administer with caution and closely monitor for adverse effects.